Catalyst Pharmaceutical (CPRX) reported $141.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 43.6%. EPS of $0.68 for the same period compares to $0.38 a year ago.
The reported revenue represents a surprise of +8.92% over the Zacks Consensus Estimate of $129.84 million. With the consensus EPS estimate being $0.53, the EPS surprise was +28.30%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product revenue,net- FIRDAPSE: $83.73 million compared to the $77.44 million average estimate based on four analysts.
- Revenue- Product revenue,net- FYCOMPA: $35.63 million versus $31.80 million estimated by four analysts on average.
- Revenue- Product revenue,net- AGAMREE: $22.04 million compared to the $20.04 million average estimate based on four analysts.
- Revenue- Product revenue,net: $141.40 million versus $129.40 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +43.6% change.
- Revenue- License and other: $0.02 million versus $0.88 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -69.1% change.
View all Key Company Metrics for Catalyst here>>>
Shares of Catalyst have returned +7.8% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
